SOPHiA DDM™
Diagnostics

Advancing precision medicine with next generation genomics solutions

We empower your precision medicine strategy and expand global access to innovative therapies by developing and deploying genomics applications at scale.

Drive global health equity through
access to genomics solutions

Genomic information is key for matching patients to the right clinical trials and treatments, but global adoption of genomic testing has been slow and disparate. Leverage SOPHiA GENETICS’ expertise in developing and deploying genomics applications in laboratories across the world to strengthen your clinical development programs and improve patient access to precision medicines.

*SOPHiA DDM^TM Clinical Trial Assay and SOPHiA DMM^TM Follow-on Dx can be further validated to Companion Diagnostic (CDx) level

Optimizing outcomes at each stage of drug development

Enhance your clinical research with exploratory testing

SOPHiA DDM™ enables accurate identification of specific molecular profiles associated with the target population(s) in your clinical research program.

Our sophisticated genomics assays can be used for your research programs to empower your early discovery. By equipping your in-house labs or leveraging leading CROs, we help you confidently select the most promising biomarker targets from your samples, enabling you to maximize the value of your samples from the very start of your research.

Reliable insights

Precisely analyze your samples and confidently generate robust and accurate insights with SOPHiA DDM™.

Data control

Access data securely stored in
SOPHiA DDM™ as needed for aggregated modelling or data re-analysis.

Fast turnaround times

Accelerate your clinical research with an efficient, end-to-end workflow, built on the expertise of our data scientists.

Elevate your research with robust clinical trial assays

Design, co-develop, and optimize high-quality and IVD-compliant Clinical Trial Assays (CTAs) & algorithms with guidance from our technical and scientific experts.

Maximize the success of your clinical trial with a fit-for-purpose CTA and through collaboration with SOPHiA GENETICS in all regulatory and development activities.

Expert-led panel design

Benefit from proven genomics expertise in designing, developing, and optimizing solutions with flexible NGS workflows.

Tailored solutions

Leverage existing RUO and IVD marked NGS-based applications that can be further validated to CTA, IUO or CDx level.

Optimized usability

Implement SOPHiA DDM™ CTA for clinical trial screening, patient selection, enrollment and stratification.

Transform your drug development with end-to-end CDx

Maximize the time and resources allocated to your clinical research program by co-developing robust end-to-end NGS-based Companion Diagnostics (CDx) solutions tailored to your specific needs.

Leveraging the SOPHiA DDM™ Platform, our proprietary genomics assays, our technical and regulatory expertise, we help you go beyond custom assay development, through regulatory approval and commercialization, accelerating your CDx market access and bringing life-changing therapies to patients sooner.

Optimized workflows

Achieve precise and steadfast analytical results with streamlined end-to-end NGS workflows optimized for predictive assays.

Trusted regulatory support

Advance your CDx development with our in-house regulatory expertise for a successful approval and immediate commercialization.

Global implementation

Harness the power of the SOPHiA DDM™ network to upscale the deployment and maximize the decentralization of your newly developed CDx.

Extend your precision therapy to underserved markets

SOPHiA DDM™ accelerates and streamlines the development of customized genomics assays that are compliant with IVDR for post-market adoption in key emerging markets.

Go beyond single-site CDx strategies to meet global regulatory and reimbursement requirements and maximize patient access to new precision therapies in undeserved markets through the scalable and universal analytical power of SOPHiA DDM™.

Global partner network

Enable sustainable and affordable patient access by supporting local adoption of genomics applications through the SOPHiA DDM™ decentralized network.

Accurate analyses

Rely on best-in-class, AI/ML-powered algorithms to accurately analyze and standardize the data generated within and across labs at scale.

Post-commercial support

Leverage customized support to promote the adoption of new diagnostic solutions with our SOPHiA DDM™ Sponsored Testing and MaxCare Program.

Broaden your reach by driving global testing adoption

With the decentralized SOPHiA DDM™ Platform, and support from the SOPHiA DDM™ MaxCare Program, you can empower rapid local and global adoption of key genomics applications enabling labs with accurate testing capabilities and increased confidence in their results.

Empower your efforts to widen adoption of high-quality, robust, and standardized genomic testing, required for access to today’s precision therapies with SOPHiA DDM™.

Expert-led consulting

Help labs achieve robust results with
on-site consultation, and hands-on training from our team of implementation experts.

Tailored solutions

Leverage existing RUO and IVD marked NGS-based applications that can be further validated to CTA or CDx level.

Trusted results

Benefit from the SOPHiA DDM™ MaxCare Program, already completed across 360+ institutions globally, to help labs adopt and confidently scale genomic testing.

“Our collaboration with SOPHiA GENETICS has the potential to uncover genomic mutations in patients with relapsed or refractory DLBCL that correlate with clinical response to ADCT-402. The insights from this collaboration will allow us to better identify and understand the characteristics of patients who respond best to treatment.”
Patrick van Berkel
Senior VP of Research and Development
ADC Therapeutics
“Identifying patients with ecDNA-driven tumors is an area of high unmet medical need. We are pleased to partner with SOPHiA GENETICS, experts in developing cloud-based IVD NGS software algorithms, for the development of our ecDNA detection algorithm, ECHO, into a clinical trial device.”
Peter Krein
VP of Precision Medicine
Boundless Bio
“Providing laboratories with innovative solutions to enable locally-delivered HRD testing is critically important, particularly in advanced ovarian cancer, where nearly half of diagnosed patients have HRD-positive tumors. We are pleased to work with
SOPHiA GENETICS in their mission to empower laboratories with more options for HRD detection.”
Kristina Rodnikova
SVP Global Oncology Diagnostics
AstraZeneca

Our groundbreaking genomics solutions

Expand upon our expertly-designed genomics applications across various cancer types and the decentralized SOPHiA DDM™ Platform to deploy precision medicine solutions at scale.

SOPHiA DDM™ for HRD: A Snapshot of HRD-Status Footprint in the SOPHiA DDM™ Platform

VIEW INFOGRAPHIC

Webinar

Addressing Global Inequalities in Comprehensive Cancer Care

Blog

Navigating Precision Medicine: The role of Companion Diagnostics

Case Study

Case Study: Breaking Data Silos for Rapid Enrollment in Lung Cancer Clinical Trials

Case Study

BRCA Analysis: Expanding Global Access with the SOPHiA DDM™ Platform

SOPHiA DDM™
Diagnostics

Advancing precision medicine with next generation genomics solutions

Drive global health equity through
access to genomics solutions